Macrolide Antibiotics Market Information: By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), By Route of Administration (Oral, Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, others), By End User (Hospitals, Dermatology Clinics, Pharmaceutical Companies, others) - Global Forecast till 2023
Macrolides are a class of antibiotics derived from Saccharopolyspora erythraea. They inhibit protein synthesis in bacteria by binding to the 50S ribosomal element and effective against gram positive bacteria and intracellular pathogens such as Legionella, Mycoplasma, and Chlamydia.
It primarily act as a bacteriostatic agent against many strains of Corynebacteria, Listeria, Moxicella, Streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp. The Global Macrolide Antibiotics Market is expected to grow at a CAGR of 12.5% during the forecast period from 2017-2023.
The market of macrolide antibiotics exhibits a significant growth across the globe owing to the increasing prevalence of skin infections and growing demand for drugs against bacterial skin infections.
Major concerns involved in the use of macrolide antibiotics are GI disturbances and inhibition of hepatic metabolism. According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the market over the review period.
Regional Analysis of the Global Macrolide Antibiotics Market:
The American region accounted for the largest share of the global market due to increasing prevalence of skin infections, and presence of prominent market players. The prevalence of bacterial skin infection increasing in the US from the last few years.
the number of visits to the emergency department has increased. Furthermore, increasing dose of antibiotics in number of out-patient settings in the U.S, which will drive the growth of the market over the forecast period.
Europe is the second largest market that holds a noticeable share of the global macrolide antibiotics market. In France, prevalence of symptomatic cat-scratch disease has been increasing from the last few years.
In Asia Pacific, prevalence of skin disease is found to be increasing in Japan. Rising prevalence of skin diseases, and growing awareness about the use of macrolides for the treatment of uncomplicated skin infections drives the market in Asia Pacific.
The Middle East and Africa show steady growth in the macrolide antibiotics market.
The Major Key players profiled in the report are Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd.
(Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.).
Major TOC for Macrolide Antibiotics Market:
1 Report Prologue 2 Market Introduction 2.1 Introduction2.2 Scope of Study2.3 Research Objective2.4 Assumptions & Limitations2.4.1 Assumptions2.4.2 Limitations
Report: www.marketresearchfuture.com/check/4342 .
3 Research Methodology 3.1 Research Process3.2 Primary Research3.3 Secondary Research4 Market Dynamics 4.1 Drivers4.2 Restraints
Category: Market Research Publishers and RetailersCompany profile: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
For more information: